Review
Copyright ©2006 Baishideng Publishing Group Co.
World J Gastroenterol. May 14, 2006; 12(18): 2876-2883
Published online May 14, 2006. doi: 10.3748/wjg.v12.i18.2876
Table 1 Role of immune responses in chronic HBV carrier
HBV carriersPossible causes
A: Acquisition of chronic StateA: Neonates of HBV- carrier mothersInability to induce HBV- specific immunity
B: Immune suppressed Individuals
B: Induction and Progression of HepatitisChronic hepatitis BAccumulation of non-specific lymphocytes
C: Recovery from chronic HBV infectionA: Natural recoveryA: Strong and multispecific
B: Acute hepatitisHBV-related immune
C: By antiviral drugsresponses
B: Antiviral therapy effective in immune modulatory phase
Table 2 Vaccine therapy in patients with chronic hepatitis B. The criteria of response to this therapy have been determined by individual investigators
ProtocolResponseReference
HBsAg/pre S2, 3 timesResponders:Pol et al[20]
12 of 32 (38%)
HBsAg/anti-HBs vaccine;Responders:Wen et al[21]
3 times9 of 15 (60%)
PreS2/S, 3 timesResponders:Pol et al[22]
(controlled trial)18.8%
HBsAg; 12 timesRespondersHoriike et al[23]
(1 yr: 55%, 2 yr: 77%)
PreS2 vaccine; 3 timesResponders: 60%Senturk et al[24]
S/pre S2; 6 timesDecreased HBV DNARen et al[25]
HBsAg/preS2; 3 timesImmune tolerant phage:Dikici et al[26]
no significant change
PreS2; 3 timesanti-HBs; 3 of 31 casesYalcin et al[27]
Combination of lamivudineHBV DNA negativationHoriike et al[28]
and HB vaccinein all 15 cases at 1 yr